In addition to the shares sold in the underwritten public offering, Lexicon granted the underwriters a 30-day option to purchase up to an additional 4,800,000 shares of common stock at the public ...

As consumer interest in eye health supplement options continues to grow heading into 2026, updated product disclosures for LuminEye Nano-Drops have recently become publicly available. With more people ...

A 2026 informational overview of the Laughland whitening kit covering publicly available ingredient disclosures, product details, refund policies, and what consumers commonly research before ...

The inducement grants were approved by ORIC’s Compensation Committee of the Board of Directors, as required by Nasdaq Rule 5635 (c) (4), and were granted as a material inducement to employment in ...

Part of a USD 23 billion US investment to expand R&D and advanced manufacturing to reach more patients ...

The registrational TACTI-004 Phase III has enrolled 378 patients globally and enrolment continues its robust pace. Additionally, over 140 clinical sites are now activated across 27 countries. The ...

OCALA, Fla., Feb. 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today that it will participate in the Corporate Connect Webinar Series hosted by ...

Conference: Piper Sandler Virtual Novel Targets in Immunology Symposium Format: Fireside chat Presenters: Taylor Schreiber, M.D., Ph.D., Chief Executive Officer, Andrew R. Neill, Chief Financial ...

Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ21.6 ...

SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company") and EMJ Crypto Technologies ("EMJX"), a digital-asset treasury operating platform with which the Company has entered into a definitive ...

Immunovant (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported its financial results for the third quarter ended ...

Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated, “We are pleased to share data at this year’s ACTRIMS annual meeting, including updates from the ENABLE real world study ...